Gavreto

Generic name: pralsetinib
Drug class: Multikinase inhibitors
Dosage form: capsule
Root of administration: oral
Dose: 200, 400 mg
Mechanism of action: The mechanism of action of Gavreto involves its ability to selectively inhibit RET kinase activity. RET is a receptor tyrosine kinase that plays a role in cell growth and survival. In some cancer cases, RET gene alterations, such as fusions or mutations, can lead to abnormal activation of the RET signaling pathway, promoting cancer cell proliferation and survival.
Drug usage cases: Gavreto is a tyrosine kinase inhibitor that may be used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic). It is only used if your cancer has a specific genetic marker (an abnormal “RET” gene fusion). Your doctor will test you for this gene fusion using an FDA-approved test.
Drug contraindications: There are no contraindications to the use of Gavreto.
Side effects: Warnings: Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use. Gavreto may affect the way other medicines work, and other medicines may affect how it works. Coadministration with strong or moderate CYP3A inhibitors, P-gp inhibitors, or strong or moderate CYP3A inducers is not recommended.
Use during pregnancy or breastfeeding: Gavreto can harm an unborn baby. Do not breastfeed while using this medicine, and for at least 1 week after your last dose.